Minutes: Steering Board meeting 12 and 16 February 2021

1. AstraZeneca – Update on Delivery Schedule

AstraZeneca representatives updated the Members of the Steering Board on the:

1. 

2. WHO interim recommendations on AstraZeneca COVID-19 Vaccine, outlining that:
   
   ➢ While vaccine supplies are limited, it is recommended that priority be given to health workers at high risk of exposure and older people, including those aged 65 or older.

   ➢ Vaccination is recommended for persons with comorbidities that have been identified as increasing the risk of severe COVID-19, including obesity, cardiovascular disease, respiratory disease and diabetes.

   ➢ Countries can refer to the WHO Prioritization Roadmap and the WHO Values Framework as guidance for their prioritization of target groups.

3. 

   ➢ 

   ➢ 

   ➢ 

   ➢
2. **Moderna – Update on Delivery Schedule**

In a dedicated meeting, Moderna representatives provided an estimated delivery schedule, outlining:

- the gradual increase in volume in January and February;
- Moderna continues to expect to meet the quarterly commitments including for manufacturing ramp up progresses as expected;
- deliveries scheduled for the week on 22 February).

The Company provided an updated weekly estimated delivery schedule for each Member State,
Furthermore, the company outlined that:

- therefore, closer to the delivery dates it would be able to be more precise on the exact delivery date;

The Commission and MSs showed coordination, outlining that:

- the company needed to greatly improve in Q2;

The company outlined the very good functioning of the plant, which started production and that it was currently producing. In the context, the company was very confident.

The company outlined that the schedule for March would be provided around 20th of February.

Ordinary Steering Board

1. Update on the allocation of doses

**Moderna** - the distribution of the top-up doses was finalised.

**Novavax** - the Members were required to provide feedback by cob the following Monday.

**Valneva** - it was agreed that the
2. Update on ongoing negotiations and discussions with other companies

**Pfizer/BioNTech II** - since *no MSs had any bank holiday*, it was considered that the five-day opt out period would finish as originally foreseen and the contract could be signed the following week.

**Novavax** - discussions on the contract were ongoing.

**Moderna II** - clauses of the new PA were discussed and the way forward was agreed among the SB.

   The Members agreed to the clauses of the Purchase Agreement and agreed to go ahead with its adoption the following week.

3. Update on the implementation of contracts and deliveries

**Pfizer/BioNTech** - the company sent a Declaration under the proposed mechanism, to be filled in by those MSs wanting a [redacted].

   Whereas some MSs outlined having [redacted].

   One MS stressed that it would prefer this period to cover the month of [redacted].

4. **COVAX** latest developments

   The Commission informed and the SB discussed about:

   - the WHO interim recommendations on AstraZeneca COVID-19 Vaccine, outlining that the next step would be granting the emergency approval;
   - ongoing work on the vaccines sharing mechanism;
   - the ongoing work on the Commission’s communication to boost capacity production.
An extraordinary Steering Board meeting was convened on 16 February on the Moderna II Purchase Agreement, in order to:

- present the contract and its key elements;
- get the approval of the Steering Board, which would allow finalising the process;
- inform on the next steps in the procedure.

The Members were informed that the contract was

The Members received detailed information of the key elements:

- number of doses: additional purchase of ( in 2021 and an option to purchase an additional in 2022),
- price, options structure and upfront payment.

The Members States welcomed the content of the contract and agreed to its adoption by the Commission on the following day.

The Purchase Agreement was to be transmitted to the Member States on following day, which would trigger the five day opt-out period.

None of the Members States indicated any intention to opt out.